Drugs / Humalog® Mix25
Humalog® Mix25
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01175811 | Feb 2011 → Nov 2012 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
Also used as a comparator or background therapy in 9 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT05373212 Comparator | May 2022 → Jan 2023 | type 2 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT05373186 Comparator | May → Dec 2022 | — | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT03180710 Comparator | Jun → Aug 2017 | type 2 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT02915250 Comparator | Oct 2016 → Jun 2017 | type 2 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT02514850 Comparator | Jul → Nov 2015 | type 2 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT02514954 Comparator | Jul → Nov 2015 | type 1 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT01981031 Comparator | Nov → Dec 2013 | type 1 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04023344 Comparator | Mar 2018 → Jan 2019 | type 2 diabetes mellitus | Geropharm | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03606018 Comparator | Apr → Jul 2017 | — | Geropharm | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Humalog Mix 25 | “Postprandial Blood Glucose Control With BioChaperone® Combo and Insulin Lispro (Humalog®) Mix 25 in People With Type 1 Diabetes Mellitus” NCT02514954 ↗10“a biosimilar insulin GP-Lis25 and a reference insulin Ly-Lis25 (Humalog Mix 25)” PMID 33355484 ↗ Dec 2020 |
| Known as | Insulin Lispro Premix | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01175811 ↗ |
| Known as | Ly-Lis25 | “a biosimilar insulin GP-Lis25 and a reference insulin Ly-Lis25 (Humalog Mix 25)” PMID 33355484 ↗ Dec 2020 |
| Modality | Protein / enzyme biologic | “reference insulin Ly-Lis25 (Humalog Mix 25)” PMID 33355484 ↗ Dec 2020 |
| Route | Subcutaneous | “administered subcutaneously for 24 weeks” NCT01175811 ↗ |